v3.26.1
Description of Business, Basis of Presentation, and Significant Transactions (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Mar. 13, 2026
Apr. 30, 2026
Jun. 30, 2026
Jun. 30, 2026
Jun. 30, 2025
Jul. 12, 2024
Jun. 04, 2024
Feb. 05, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Sale of future royalties, intellectual property, and other assets, net       $ 48,935 $ 0      
Impairment of intangible assets       $ 43,300        
Common stock registered, shares (in shares)               2,269,721
Common stock, registered maximum offering price             $ 350,000  
ATM Agreement Sales                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Common stock, registered maximum offering price             $ 75,000  
JMP | ATM Agreement Sales                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Aggregate offering price           $ 75,000    
Percentage of aggregate gross sales proceeds           3.00%    
Stock issued (in shares)       0        
Commave Settlement Agreement                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Royalty percentage       10.00%        
Commave Settlement Agreement | Commave Therapeutics SA                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Sale of future royalties, intellectual property, and other assets, net $ 50,000              
Commave Settlement Agreement | Commave Therapeutics SA                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Payments to acquire intangible assets   $ 5,000 $ 45,000          
Commave Settlement Agreement | Commave Therapeutics SA | Aquestive Therapeutics                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Payments to acquire intangible assets   500 4,500          
Commave Settlement Agreement | Commave Therapeutics SA | Zevra Therapeutics                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Payments to acquire intangible assets   $ 4,500 $ 40,500          
Commave Settlement Agreement | Aquestive Therapeutics | License                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Royalty percentage       10.00%